OZOrçun Zorbozan

Orçun Zorbozan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Orçun Zorbozan has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers
    Open Access

    Basic Microbiome Analysis: Analytical Steps from Sampling to Sequencing

    by Gülfem Ece, Ahmet Aktaş, Özlem Koyuncu Özyurt, Hadiye Demirbakan, Hikmet Eda Alışkan, İmran Sağlık, Orçun Zorbozan, Alev Çetin Duran, Ayşe Rüveyda Uğur, Duygu Öcal, et al.

    The human microbiome is increasingly recognized as a key determinant of health and disease, yet methodological variability continues to limit reproducibility and clinical translation of findings. This review synthesizes current approaches in microbiome research, critically evaluating each step from sampling to sequencing and downstream bioinformatics. Pre-analytical factors such as sample type, collection method, preservation, and storage conditions profoundly affect microbial community profiles and remain a major source of bias. Nucleic acid extraction protocols and quality assessment strategies are discussed with emphasis on optimized lysis techniques, contamination controls, and DNA yield evaluation. Advances in sequencing technologies are highlighted, including 16S rRNA amplicon sequencing, shotgun metagenomics, third-generation long-read platforms, and emerging single-cell and minimal-input methods, each with specific advantages and limitations in taxonomic and functional resolution. Bioinformatics pipelines for taxonomic profiling, variant detection, phylogenetic inference, and functional annotation are compared, with attention to widely used reference databases such as RefSeq, GTDB, and SILVA. Integrative multi-omics approaches, including metatranscriptomics, metabolomics, and genome-scale metabolic modeling, are presented as powerful tools for linking microbial community structure to host physiology and disease mechanisms. Despite these advances, the lack of standardized workflows across pre-analytical, sequencing, and computational steps continues to hinder inter-study comparability and biomarker validation. This review aims to provide a methodological framework that highlights both strengths and limitations of current technologies while underlining the need for harmonized protocols to ensure reproducibility and accelerate the translation of microbiome research into clinical practice.


  • Unnecessary Repeated Tests in The Biochemistry Laboratory

    by Nergiz Zorbozan, Elif Fırat, Orçun Zorbozan

    Amaç: Bu çalışmanın amacı, minimum yeniden test aralıklarına dayanarak “tekrarlanan testler” ve “gereksiz tekrarlanan laboratuvar testleri”ni değerlendirmektir. Gereç ve Yöntem: 2023 yılı boyunca İzmir Kemalpaşa Devlet Hastanesi laboratuvarında çalışılan tiroid uyarıcı hormon (TSH), ferritin, C-reaktif protein (CRP) ve eritrosit sedimantasyon hızı (ESH) testlerine ait veriler laboratuvar bilgi yönetim sisteminden retrospektif olarak elde edildi. Bu testler için minimum yeniden test aralıkları; The Royal College of Pathologists, The Association for Clinical Biochemistry and Laboratory Medicine ve The Institute of Biomedical Science tarafından geliştirilen Ulusal Patolojide Minimum Yeniden Test Aralıkları kılavuzuna göre belirlendi. Buna göre minimum yeniden test aralıkları; TSH için 28 gün, ferritin için 30 gün, CRP için 24 saat ve ESH için 7 gün olarak kabul edildi. Çalışma süresi boyunca bir hastada birden fazla kez yapılan testler “tekrarlanan testler” olarak, minimum yeniden test aralığından daha kısa sürede tekrar edilen testler ise “gereksiz tekrarlanan testler” olarak sınıflandırıldı. Bulgular: Laboratuvarda yapılan toplam TSH, ferritin, CRP ve ESH test sayıları sırasıyla 27.516, 19.836, 32.100 ve 7.200 olarak belirlendi. Tekrarlanan testlerin sayısı (yüzdesi) TSH için 1.402 (%5,10), ferritin için 1.726 (%8,70), CRP için 1.827 (%5,69) ve ESH için 1.020 (%14,2) idi. Bu tekrarlanan testler içerisinde gereksiz tekrarlanan test olarak sınıflandırılanların sayısı (yüzdesi) sırasıyla 148 (%10,6), 134 (%7,76), 118 (%6,46) ve 107 (%10,49) olarak hesaplandı. Sonuç: Gereksiz tekrarlanan laboratuvar testleri, sağlık hizmetlerinde maliyet artışına ve iş yükü verimsizliğine önemli ölçüde katkıda bulunmaktadır. Gereksiz testlerin yaygınlığı konusunda sağlık yöneticileri ve klinisyenlerin farkındalığının artırılması, kaynak kullanımının iyileştirilmesi ve önlenebilir harcamaların azaltılması açısından kritik öneme sahiptir.

  • Open Access

    The Urogenital System Microbiota: Is It a New Gamechanger in Urogenital Cancers?

    by Gülfem Ece, Ahmet Aktaş, Ayse Caner, İmran Sağlık, Tuğba Kula Atik, Özlem Ulusan Bağcı, Fulya Bayındır Bilman, Hadiye Demirbakan, Seda Güdül Havuz, Esra Kaya, et al.

    The human microbiome, which encompasses microbial communities and their genetic material, significantly influences health and disease, including cancer. The urogenital microbiota, naturally present in the urinary and genital tracts, interact with factors such as age, lifestyle, and health conditions to affect homeostasis and carcinogenesis. Studies suggest that alterations in this microbiota contribute to the development and progression of genitourinary cancers, emphasizing the concept of oncobiome, which refers to microbial genetic contributions to cancer. Similarly, gut microbiota can influence hormone levels and systemic inflammation, impacting cancers such as cervical and prostate cancer. Advanced studies indicate that microbial communities in genitourinary cancers have distinct profiles that may serve as diagnostic biomarkers or therapeutic targets. Dysbiosis of the urinary microbiota correlates with bladder and kidney cancer. Additionally, gut microbiota influence the effectiveness of cancer treatments. However, further research is necessary to clarify causality, the role of microbial metabolites, and hormonal regulation. The aim of this review is to understand that these dynamics present opportunities for innovative cancer diagnostics and therapies, highlighting the need for integration of microbiology, oncology, and genomics to explore the role of microbiota in genitourinary cancers. For this, a comprehensive search of relevant databases was conducted, applying specific inclusion and exclusion criteria to identify studies examining the association between microbiota and urogenital cancers. Research into the mechanisms by which microbiota influence urogenital cancers may pave the way for new diagnostic and therapeutic approaches, ultimately improving patient outcomes.


  • Top Cited Papers
    Open Access

    Clinical practice guidelines for the diagnosis and treatment of scabies

    by Soner Uzun, Murat Durdu, Aslan Yürekli, Mehmet K. Mülayim, Melih Akyol, Sevtap Velipaşaoğlu, Mehmet Harman, Ayşegül Taylan‐Özkan, Ekin Şavk, Devrim Demir‐Dora, et al.

    Scabies, caused by the Sarcoptes scabiei var hominis mite burrowing into the skin, is a highly contagious disease characterized by intense nocturnal itching. Its global impact is considerable, affecting more than 200 million individuals annually and posing significant challenges to healthcare systems worldwide. Transmission occurs primarily through direct skin‐to‐skin contact, contributing to its widespread prevalence and emergence as a substantial public health concern affecting large populations. This review presents consensus‐based clinical practice guidelines for diagnosing and managing scabies, developed through the fuzzy Delphi method by dermatology, parasitology, pediatrics, pharmacology, and public health experts. The presence of burrows containing adult female mites, their eggs, and excreta is the diagnostic hallmark of scabies. Definitive diagnosis typically involves direct microscopic examination of skin scrapings obtained from these burrows, although dermoscopy has become a diagnostic tool in clinical practice. Treatment modalities encompass topical agents, such as permethrin, balsam of Peru, precipitated sulfur, and benzyl benzoate. In cases where topical therapy proves inadequate or in instances of crusted scabies, oral ivermectin is recommended as a systemic treatment option. This comprehensive approach addresses the diagnostic and therapeutic challenges associated with scabies, optimizing patient care, and management outcomes.


  • Unpleasant Souvenir: Imported Plasmodium falciparum Malaria in Türkiye

    by Ahmet Özbilgin, Varol Tunalı, Şebnem Şenol Akar, İbRahim Çavuş, Orçun Zorbozan, Ahmet Yıldırım, Nevin Turgay

    Each year, approximately 125 million people visit malaria-endemic countries. This study aimed to investigate the clinical characteristics of imported Plasmodium falciparum malaria infections in Türkiye. The study included patients diagnosed with P. falciparum malaria between 1996 and 2022. A retrospective evaluation was conducted on whole blood samples and/or blood smears, as well as detailed medical histories, clinical manifestations, and laboratory findings. A total of 131 imported cases of P. falciparum were included in the study. Among the patients, 121 were male. Of these, 101 had traveled to Africa, while 30 had visited Asia. Among the patients, 109 were returned travelers, and 22 were refugees/migrants. Early trophozoites were observed in all patients, while gametocytes were detected in 30 patients. Cerebral malaria developed in 15 patients, resulting in the death of two individuals. Additionally, 10 patients received preventive chemoprophylaxis. Turkey is situated on migration routes that connect two continents to Europe, where more than 95% of the global malaria burden exists. The importation of malaria through returned travelers poses a risk of malaria reintroduction in our country, given the presence of suitable vectors, climate conditions, and environmental factors. Importantly, 30 patients (22.9%) exhibited gametocyte forms of P. falciparum, which have the potential to infect Anopheles species, thus establishing a basis for local malaria transmission.


  • Monitoring the Trends in Intestinal Parasite Frequencies; 2018 and 2022 Data

    by Orçun Zorbozan, Nevin Turgay

    Monitoring intestinal parasite frequencies is effective on diagnosis, treatment, and prevention strategies to be developed against these parasites. In this study, it was aimed to reveal the parasite species and frequency data of stool samples in parasitology direct diagnosis laboratory. Stool parasitological examination results were obtained retrospectively from our laboratory internal quality control data tables. Data belonging to the year 2018 and 2022 were compared retrospectively. Annual parasites detected in stool samples were 388 of 4.518, and 710 of 3.537, in 2018 and 2022, respectively. Frequency of parasite detection in stool samples was found to be significantly higher in 2022 (pBlastocystis spp., Enterobius vermicularis, Cryptosporidium spp., Giardia intestinalis and Entamoeba histolytica in 2018, respectively; and Cryptosporidium spp., Blastocystis spp., Cyclospora spp., Entamoeba dispar and Giardia intestinalis, in 2022, respectively. Cryptosporidium spp., Cyclospora spp. and Entamoeba dispar increased significantly, while Blastocystis spp. and Enterobius vermicularis decreased significantly, in 2022. According to the data obtained, causative agents for intestinal parasitic infections were protozoans, especially Cryptosporidium spp. It has been concluded that tightening the measures for protection of water with one health approach and improving the education and habits of society on personal hygiene and food safety can be effective in reducing the frequency of intestinal parasite infections in our region.


  • Investigation of in vitro Efficacy of Miltefosine on Chronic Cutaneous Leishmaniasis

    by Varol Tunalı, Mehmet Harman, İbRahim Çavuş, Orçun Zorbozan, Ahmet Özbilgin, Nevin Turgay

    Leishmaniasis is the second deadliest parasitic disease in the World Health Organisation's list of neglected diseases, following malaria. Cutaneous leishmaniasis (CL) is the most common form of the disease and it is one of the few communicable diseases with increasing incidence rates owing to factors like armed conflicts and climate change. CL can be divided into two major groups: Acute CL (ACL) and chronic CL (CCL). The aim of this study was to compare the in vitro efficacy of miltefosine and pentavalent antimony compounds in the CCL patient samples. Five isolates previously isolated from 5 CCL patients were included in this study. Genotyping is performed using internal transcribed spacer 1 (ITS 1) gene region real-time PCR. In vitro drug efficacy tests were applied to determine their activity against meglumine antimoniate (MA) and miltefosine. Serial dilutions (512, 256, 128, 64, 32, 16, 8 and 4 µg/mL) prepared from MA and miltefosine were prepared in 96-well flat-bottom cell culture plates and incubated at 24 °C for 48 hours. The efficacy of the drug on Leishmania spp. promastigotes after 24 and 48 hours was evaluated by hemocytometer slide and XTT cell viability test. All of the samples were genotyped as L. tropica. Evaluation of 24 and 48 hours showed, 128 µg/mL and 256 µg/mL and 32 µg/mL and 64 µg/mL concentrations of miltefosine and MA were enough to kill all the promastigotes respectively. The results of the hemocytometer slide and XTT were consistent. There are no studies investigating the in vitro efficacy of miltefosine with the CCL patient group. To overcome the treatment challenges experienced in this special patient group, more studies are needed. According to our results, it is concluded that miltefosine is efficient for the treatment of CCL and further clinical studies with miltefosine will reveal valuable data.


  • The Impact of COVID-19 Pandemic on Access to Healthcare: The Experience of the Diagnostic Parasitology Laboratory of Ege University

    by Orçun Zorbozan

    Beyond the Coronavirus disease-2019 (COVID-19) itself, the pandemic influenced healthcare settings in all aspects. It is aimed to demonstrate the effect of the pandemic on access to the healthcare setting in the parasitology direct diagnosis laboratory. Stool parasitological examination results were obtained retrospectively from the laboratory information system. Data belonging to the one-year of pandemic, lock-down and gradual normalization periods and their time equivalents were compared retrospectively. During pandemic, parasites were detected in 529 of 2.233 samples. Parasites were detected in 58 of the 178 samples during the lock-down period and 471 of the 2.055 samples in the gradual normalization period. Incidence of Cryptosporidium spp. increased during the pandemic and lock-down periods. Incidence of Blastocystis spp. decreased during the pandemic and gradual normalization periods. Incidence of Giardia intestinalis decreased during the pandemic and gradual normalization periods. Incidence of Entamoeba histolytica/dispar increased during the pandemic and gradual normalization periods Incidence of Cyclospora spp. increased during the pandemic and gradual normalization periods. Incidence of Enterobius vermicularis decreased during the pandemic and gradual normalization periods and no case was seen during the lock-down period. Although the incidence of parasites gives the impression that COVID-19 does not cause weakness in the fight against intestinal parasitic diseases, there may be parasitic infections with a similar frequency in the society that cannot access the laboratory. It is predicted that the effects of this vulnerability may lead to an increase in the incidence of parasites in postpandemic period.


  • Evaluating the Glucantime Concentration for the ex vivo Glial Cell Model of Antimony-resistant Leishmania tropica Amastigotes

    by Orçun Zorbozan, Vedat Evren, Mehmet Harman, Ahmet Özbilgin, Özlem Alkan Yılmaz, Nevin Turgay

    Because the protocols used in the treatment of leishmaniasis can be toxic and have many limitations, such as the development of resistance against such protocols, new treatment options are needed, especially against resistant patients. Ex vivo models may be a good source for evaluating new drug options for patients with antimony-resistant parasites. This study aimed to evaluate the Glucantime concentration for our ex vivo glial cell amastigote model we had defined in previous work. We prepared the astroglial cell culture from brains of 2 to 3 day old neonatal Sprague-Dawley rats under sterile conditions by modifying McCarthy's method. Four plates of cells were infected with antimony-resistant Leishmania tropica promastigotes. After 24 h of incubation, we added Glucantime to 3 plates with different concentrations. After 72 h, we removed the supernatant and then dried, fixed, and stained the plates with Giemsa to count the amastigotes in the glial cells. We observed the amastigotes in glial cells in the control flask. Glial cells were ruined in flasks, which include 75 μg/mL and 37.5 μg/mL Glucantime. The number of amastigotes per 100 glial cells was 116 for the flask with 7.5 μg/mL Glucantime concentration, while 487 for the control flask. We found that while high concentrations of Glucantime were toxic for glial cells, 7.5 μg/mL Glucantime concentration managed to reduce the number of Leishmania tropica amastigotes in glial cells.


  • Open Access

    Biosafety Risk Assessment of a Routine Diagnostic Laboratory During the Coronavirus Disease 2019 Pandemic

    by Orçun Zorbozan, Nergiz Zorbozan, Nevin Turgay

    Background: In this study, we aimed to perform a biosafety risk assessment to determine measures to be taken against coronavirus disease 2019 (COVID-19) in the routine diagnostic parasitology laboratory of a tertiary health care center. Methods: The risk assessment template included in the supplement of the interim guidance of “WHO Laboratory Biosafety Guidance Related to COVID-19” was used for the risk assessment. Risk assessments were carried out for the “diagnosis of protozoan diseases in respiratory tract samples” and “diagnosis of intestinal parasitic diseases” processes. Initial risk of the laboratory activities was determined before additional risk control measures and overall initial risk was estimated for each process. Overall residual risk of the laboratory activities after risk control measures was estimated for each process. Results: Overall initial risk for both processes was “very high.” Fresh microscopic examination steps in both processes and concentration steps for “diagnosis of intestinal parasite diseases” were discontinued. All aerosol-generating steps were moved into a class-IIA biological safety cabinet. Overall residual risk was “medium” for both processes. Conclusion: This study serves as an example for clinical laboratories regarding how the risk assessment approach in guidelines can be transferred to daily practice.